- Companies
- TMRW Life Sciences
TMRW Life Sciences Funding, Investors & Competitors
TMRW Life Sciences has raised $182M across 4 funding rounds, most recently a $28M Series D in July 2024.
Last TMRW Life Sciences funding round
$28M
Series D · Jul 2024
Cumulative funding TMRW Life Sciences raised
$182M
across 4 funding rounds
Key investors in TMRW Life Sciences
5AM Ventures
GV
Casdin Capital
Presight Capital
Transformation Capital
What If Ventures
Special Situations Life Sciences Innovation Fund
Peter Thiel
About TMRW Life Sciences
TMRW Life Sciences is a New York-headquartered life sciences technology firm revolutionizing IVF and cell management with automated cryo-storage platforms. Founded in 2018, it provides robotic monitoring systems and digital chain-of-custody solutions for eggs and embryos, reducing errors in fertility clinics worldwide.
Founded
2018
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
TMRW Life Sciences Funding History
TMRW Life Sciences has raised a total of $182M across 4 funding rounds.
TMRW Life Sciences' first fundraising round was a $12M Series A in May 2019. The most recent completed round was a $28M Series D in July 2024.
TMRW Life Sciences funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Jul 2024 | Series D | 5AM Ventures (lead); DF Investment Partners; GV; Amy Schumer; Casdin Capital; LSI (Life Science Innovations Fund); FIOS Venture Holdings; Presight Capital; What If Ventures; Transformation Capital | $28M | TMRW Life Sciences is the creator of the first and only FDA-cleared automated specimen management and storage platform for frozen human sperm, eggs, and embryos used in fertility treatment. The company's core product, CryoRobot Select, was cleared by the FDA in 2022 and provides 100 percent chain of custody through its ivfOS software-guided platform designed to eliminate sample management errors including loss of eggs and embryos and implantation mix-ups. Founded in 2018, TMRW rapidly emerged as a leader in fertility technology, earning Fast Company recognition as the most innovative biotech company in 2022. In July 2024, TMRW closed a Series D financing round of $28+ million led by 5AM Ventures with participation from FIOS Venture Holdings, DF Investment Partners, Transformation Capital, Life Sciences Innovation Fund, and Casdin Capital, alongside support from women's health focused investors including GV (formerly Google Ventures) and actress Amy Schumer. The company had previously raised $25 million in Series B funding in late 2019 and $105 million in a subsequent round in July 2021, bringing total capital raised to more than $170 million since inception. TMRW's market expansion reflects significant industry demand driven by the volume of frozen specimens in fertility clinics. More than one million frozen eggs and embryos are frozen in U.S. fertility clinics annually, and legacy storage systems have proven insufficient to safely manage this growing inventory. TMRW's five leading clinic partners account for 10 percent of all U.S. IVF activity, and by 2025 the company had expanded partnerships to more than 70 fertility clinics while collaborating with industry leaders such as IVI RMA North America and forming a strategic partnership with Cryoport Systems for specimen transport and management. A pivotal moment for TMRW's market positioning occurred in February 2024 when a fertility clinic incident in Alabama prompted the state's Supreme Court to issue a landmark ruling on frozen embryo liability, putting the industry on notice that specimen storage management failures could carry significant legal and patient safety consequences. In June 2025, TMRW further strengthened its competitive position by acquiring Cryogatt Systems' patent portfolio covering cryogenic storage and RFID-based tracking technologies, expanding its intellectual property portfolio and technological capabilities in specimen management. |
| Jul 2021 | Series C | Transformation Capital (lead); 5AM Ventures; Peter Thiel; GV; Casdin Capital; Special Situations Life Sciences Innovation Fund; Susan Wojcicki; Presight Capital; What If Ventures; Anne Wojcicki; Coriolis Ventures | $105M | TMRW Life Sciences develops the world's first automated platform for tracking, monitoring, and storage of frozen eggs and embryos used in in vitro fertilization (IVF), replacing manual analog methods to reduce errors and support scaling IVF demand projected for hundreds of millions of births. The company launched commercial operations in early 2021, securing relationships representing over one third of U.S. IVF cycles, with plans for UK and European expansion starting in 2022. TMRW's team includes serial entrepreneurs in fertility, embryology, automation, and robotics, with prior ventures sold for over $1 billion. On July 20, 2021, TMRW announced a $105 million Series C financing combining equity and debt. The equity portion was led by Transformation Capital, with participation from GV, Casdin Capital, Peter Thiel, Anne Wojcicki, Susan Wojcicki, 5AM Ventures, Life Sciences Innovation Fund (also called Special Situations Life Sciences Innovation Fund), and others including Coriolis Ventures, Presight Capital, and What If Ventures. Signature Bank expanded its debt facility. Funds were allocated to accelerate global expansion, advance product innovation, build consumer awareness, and pursue business development. CEO Tara Comonte, formerly of Shake Shack, emphasized TMRW's role in enabling IVF scale and safety amid rising demand for fertility services. Transformation Capital highlighted TMRW as emerging as the new IVF standard of care. By 2026, TMRW had raised a total of approximately $198.3 million across rounds, including later debt and a $28 million Series D in July 2024 for cryostorage demand. The company remains active and venture-backed. |
| Dec 2019 | Series B | 5AM Ventures (lead) | $37M | TMRW Life Sciences, founded in 2018 and headquartered in New York, develops ivfOS, the world's first operating system for software-guided embryology and cryo-management in IVF labs, featuring fully robotic freezers, 100% physical and digital chain of custody, continuous monitoring of egg and embryo samples, and electronically integrated processes overseen from a control center. The company announced the closing of a $25 million Series B funding round on December 17, 2019, led by 5AM Ventures, bringing total investment over the past 12 months to $39 million. This followed a May 2019 Series A of $12 million and preceded later rounds, with aggregate funding reaching $198.3 million across multiple rounds including Series D in 2024. The Series B funding supported TMRW's mission to improve IVF outcomes amid projected hundreds of millions of births from advances in fertility treatments, as highlighted by 5AM Ventures Managing Partner Andy Schwab. With the round's close, TMRW appointed Melanie Goldey as Chief Operating Officer and Chief Financial Officer. The founding team, including Joshua Abram, Alan Murray, and Dr. Jeffrey Port, consists of serial entrepreneurs whose prior ventures sold for over $1 billion combined. TMRW has since expanded, earning Fast Company’s most innovative biotech company recognition in 2022 and FDA clearance for CryoRobot Select, the first automated platform for managing and storing frozen eggs and embryos in IVF. In 2024, it exceeded its Series D financing goal of over $28 million led by 5AM Ventures, partnered with more than 70 fertility clinics, announced a partnership with Cryoport Systems for specimen management and transport, and acquired Cryogatt fertility patents to strengthen its position in fertility technology, with total funding surpassing $170 million since inception. |
| May 2019 | Series A | Special Situations Life Sciences Innovation Fund (lead) | $12M | - |
Who has invested in TMRW Life Sciences?
15 investors have backed TMRW Life Sciences across its funding rounds, including 5AM Ventures, GV, Casdin Capital, Presight Capital, Transformation Capital and What If Ventures.
Lead investors include 5AM Ventures, Transformation Capital and Special Situations Life Sciences Innovation Fund.
TMRW Life Sciences Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Dec 2019 | ||
| 2 | Participant | Jul 2021 | ||
| 2 | Participant | Jul 2021 | ||
| 2 | Lead | May 2019 | ||
| 2 | Participant | Jul 2021 | ||
| 2 | Participant | Jul 2021 | ||
| 2 | Lead | Jul 2021 | ||
| -- | 1 | Participant | Jul 2024 | |
| 1 | Participant | Jul 2021 | ||
| 1 | Participant | Jul 2024 | ||
| 1 | Participant | Jul 2024 | ||
| -- | 1 | Participant | Jul 2024 | |
| 1 | Participant | Jul 2021 | ||
This data is available for Pro users. Sign up to see all 15 TMRW Life Sciences investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialTMRW Life Sciences Competitors
TMRW Life Sciences competitors include listed companies like Siemens, Johnson & Johnson, Roche and Thermo Fisher Scientific, and private ones like Biosplice Therapeutics and Neuralink.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $91B | $15B | $234B | 2.9x | ||
| Publicly listed | $94B | $40B | $651B | 6.8x | ||
| Publicly listed | $77B | $26B | $351B | 4.9x | ||
| Publicly listed | $45B | $11B | $243B | 6.0x | ||
| Private | - | - | $12B | - | ||
| Private | - | - | $9B | - |
TMRW Life Sciences Public Comps
TMRW Life Sciences is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Schneider Electric, Abbott, ABB, Hitachi and Danaher.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $46B | $9.5B | 4.3x | 3.9x | 21.0x | 18.4x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $33B | $6.9B | 5.4x | 4.9x | 25.9x | 22.6x | |||
This data is available for Pro users. Sign up to see all TMRW Life Sciences competitors and their valuation data. Start Free Trial | ||||||||
Common questions about TMRW Life Sciences
| When was TMRW Life Sciences founded? | TMRW Life Sciences was founded in 2018. |
| Where is TMRW Life Sciences headquartered? | TMRW Life Sciences is headquartered in New York City, NY, United States. |
| Is TMRW Life Sciences publicly listed? | No, TMRW Life Sciences is a private, VC-backed company. |
| How much funding has TMRW Life Sciences raised? | TMRW Life Sciences has raised $182M across 4 funding rounds. |
| What was TMRW Life Sciences' last funding round? | TMRW Life Sciences' last funding round was a $28M Series D in July 2024, led by 5AM Ventures. |
| Who are TMRW Life Sciences' investors? | TMRW Life Sciences' investors include 5AM Ventures, GV, Casdin Capital, Special Situations Life Sciences Innovation Fund, Presight Capital, What If Ventures, Transformation Capital, DF Investment Partners, Peter Thiel, Amy Schumer and 5 others. |
| Which companies are comparable to TMRW Life Sciences? | Companies comparable to TMRW Life Sciences include Siemens, Johnson & Johnson, Roche, Thermo Fisher Scientific, Biosplice Therapeutics and Neuralink. |
See companies similar to TMRW Life Sciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




